Healthcare & Life Sciences

Experience

  • Mergers And Acquisitions

    • EQT in funds and regulatory aspects of its €450 million acquisition of Life Sciences Partners, a leading European life sciences venture capital firm.
    • HealthEdge and its controlling shareholder, Blackstone, in the acquisition of Wellframe, a digital health management company.
    • The Carlyle Group in its strategic growth investment and acquisition of a majority stake in Saama, a leading AI-driven intelligent clinical cloud company that enables the life sciences industry to conduct faster and safer clinical developments and regulatory programs, valuing the company at up to $430 million.
    • Sun Life in its $2.475 billion acquisition of DentaQuest.
    • Blackstone in its investment in Medable, the leading cloud platform for patient-centered clinical research, valuing Medable at $2.1 billion.
    • HCA Healthcare, one of the nation’s leading provider of healthcare services, in its agreement to acquire the operations of five hospitals of Steward Health Care, the largest physician-led healthcare network.
    • HCA Healthcare, one of the nation’s leading provider of healthcare services, in its agreement to divest certain assets from its joint venture with Brookdale Health Care Services to LHC Group, a national provider of in-home healthcare.
    • A major investor in Envigo, a pharmaceutical and biotechnology research provider, in the sale of Envigo to Inotiv, a drug discovery and development contract research organization, for a total transaction value of approximately $545 million.
    • Life and Specialty Ventures in its collaboration with Cambia Health Solutions, including its acquisition of LifeMap, the reinsurance and administration of Cambia dental insurance policies, and Cambia’s acquisition of an equity stake in Life and Specialty Ventures.
    • Canada Pension Plan Investment Board in its joint venture with Greystar Real Estate Partners to pursue life science real estate development opportunities in leading U.S. life science markets.
    • TPG Capital, Welsh, Carson, Anderson & Stowe and Kindred Healthcare in the sale of Kindred Healthcare to LifePoint Health.
    • Clayton, Dubilier & Rice in the financing aspects of its $3.7 billion take-private acquisition of UDG Healthcare.
    • TPG Capital, Welsh, Carson, Anderson & Stowe and Kindred at Home in the sale of Kindred at Home to Humana, valuing Kindred at Home at $8.1 billion.
    • J.P. Morgan Securities, as financial advisor to PPD, in PPD's sale to Thermo Fisher for $17.4 billion in cash plus $3.5 billion of net debt.
    • Blackstone as a lead investor in the formation of Hydrogen Health.
    • Blackstone in its investment in Ginger, a leader in on-demand behavioral healthcare.
    • CPP Investments as lead investor in a $400 million Series C financing for insitro, a machine learning-driven drug discovery and development company.
    • The Carlyle Group in the $2.5 billion merger of Grand Rounds and Doctor on Demand.
    • HCA Healthcare in its acquisition of a majority stake in Brookdale Health Care Services, the home health, hospice and outpatient therapy business of Brookdale Senior Living.
    • The Carlyle Group in its $2.6 billion sale of MedRisk to CVC Capital Partners.
    • J.P. Morgan Securities, as financial advisor to AmerisourceBergen, in AmerisourceBergen’s acquisition of Alliance Healthcare from Walgreens Boots Alliance for approximately $6.5 billion in cash and stock.
    • Special Committee of R1 RCM in its conversion of all of the Series A Convertible Preferred Stock held by an investment vehicle jointly owned by Ascension and TowerBrook to common stock.
    • HealthEdge and its controlling shareholder, Blackstone, in the acquisition of Altruista, a care management software company that delivers care management and population health management solutions that support value-based and person-centered care models.
    • Kelso & Company in the financing aspects of its acquisition of a majority stake in Refresh Mental Health.
    • Precision Medical Group in its investment from funds managed by Blackstone.
    • Morgan Stanley Capital Partners in the sale of Manna Pro Products, a recognized leader in pet care to The Carlyle Group.
    • Kindred Healthcare in the sale of its RehabCare business line, a provider of contract therapy services in 43 states, to Select Rehabilitation, a leading provider of contract rehabilitation services.
    • Blackstone in its investment in Bright Health as part of a $500 million Series E financing round.
    • The Carlyle Group in its majority investment in TriNetX, a leading global health research network optimizing clinical research to bring new therapies to market faster.
    • The Carlyle Group in its $175 million investment in Grand Rounds, a leader in healthcare quality and clinical navigation.
    • AIA in its strategic partnership with Practo, India’s leading digital healthcare platform.
    • TPG Capital in the sale of Adare Pharmaceuticals, a leading specialty contract development and manufacturing organization, to Thomas H. Lee Partners and Frazier Healthcare Partners and the related separation of Adare’s Eosinophilic Esophagitis product into a TPG-backed entity.
    • HealthEdge and its controlling shareholder, Blackstone, in the acquisition of The Burgess Group, an innovative payment integrity software company focused on improving healthcare payment operations through a cloud-based technology platform.
    • Pantheon in its equity investment as part of the proposed £2 billion takeover by KKR of John Laing Group plc.
    • Clayton, Dubilier & Rice in its $250 million convertible preferred equity investment in Covetrus, a global leader in animal-health technology and services.
    • Morgan Stanley Capital Partners and Pathway Vet Alliance in the $2.7 billion sale of a majority stake in Pathway to TSG Consumer Partners.
    • LeapFrog Investments in its investment in MedGenome, a leading genetic diagnostics, research and data company focused on expanding access for populations in South Asia and other emerging markets, with operations in the U.S., India, Canada and Singapore.
    • Blackstone in its acquisition of HealthEdge, a leading technology business that delivers next generation Core Administrative Processing Systems (CAPS) solutions to healthcare businesses.
    • Clayton, Dubilier & Rice in the financing and tax aspects of its £400 million acquisition of Huntsworth.
    • Allergan in its sale of Brazikumab to AstraZeneca and Zenpep to Nestle.
    • J.P. Morgan Securities, as financial advisor to The Medicines Co., in the $9.7 billion acquisition of The Medicines Co. by Novartis AG.
    • Clayton, Dubilier & Rice in its acquisition of Cynosure, a leader in medical aesthetics systems and technologies, from Hologic, a NASDAQ listed medical technology company primarily focused on women’s health.
    • Guggenheim Securities, as financial advisor to Menlo, in Menlo’s merger with Foamix.
    • FC Encore in the $735 million transfer of 60 healthcare facilities to Omega Healthcare Investors.
    • Prudential Financial in its $2.35 billion acquisition of Assurance IQ.
    • Centerbridge Partners in its investment in GoHealth.
    • J.P. Morgan Securities, as financial advisor to Allergan, in the sale of Allergan to AbbVie for $63 billion in cash and stock.
    • TPG Growth in its takeover of the existing assets of the Abraaj Group’s $1 billion Global Healthcare Fund. The deal saw Debevoise win the “Specialist Deal Legal Advisor” category at the Private Equity Africa Awards.
    • Guggenheim Securities and Morgan Stanley, as financial advisors to Pfizer, in its $11.4 billion acquisition of Array Biopharma.
    • Bain Capital Private Equity and Diamond Castle in the sale of Beacon Health Options to Anthem.
    • Manna Pro, a manufacturer and marketer of pet care and nutrition products and a Morgan Stanley Capital Partners portfolio company, in its acquisition of Hero Pet Brands.
    • CPPIB in its investment in a Series B fundraising in Sana Biotechnology, a U.S.-based biotech company focused on creating and delivering engineered cells as treatments for disease.
    • Deutsche Bank Securities, as financial advisor to Eli Lilly, in Eli Lilly's $8 billion acquisition of Loxo Oncology.
    • Guggenheim Securities, as financial advisor to Corium International, a commercial-stage biopharmaceutical company, in Corium’s $504 million sale to Gurnet Point Capital.
    • LeapFrog Investments in its investment in Pyramid Group, the largest distributor of cardiac and orthopaedic equipment in East Africa.
    • Prism, a leading retina surgeon practice, in its sale of a 60% stake to Quad-C Management.
    • Providence Service Corporation and LogistiCare in LogistiCare’s acquisition of Circulation, a provider of technology-enabled logistics solutions and analytics for managing non-emergency transportation across healthcare.
    • HCA Healthcare in its $1.5 billion acquisition of Mission Health, a nonprofit North Carolina health system.
    • Johnson & Johnson in its sale of Nizoral’s EMEA rights to STADA Arzeimittel AG; LATAM rights to Kramer Laboratories; and APAC rights to Alliance Pharmaceuticals Limited.
    • Johnson & Johnson in its acquisition of Zarbee's Naturals, a leader in naturally-based healthcare products.
    • Evercore and J.P. Morgan, as financial advisors to Akebia Therapeutics, in its $1.3 billion merger with Keryx Biopharmaceuticals.
    • TPG Capital and Welsh, Carson, Anderson & Stowe, with Humana, in their $1.4 billion acquisition of Curo Health Services.
    • Precision Medicine Group in a new $275 million investment.
    • Deutsche Bank Securities, as financial advisor to Mallinckrodt, in Mallinckrodt's $1.2 billion acquisition of Sucampo Pharmaceuticals.
    • TPG Capital and Welsh, Carson, Anderson & Stowe in the $4.1 billion acquisition of Kindred Healthcare.
    • Morgan Stanley Private Equity in its acquisition of Manna Pro, a leading producer of nutritional supplements and other animal products, from The Carlyle Group.
    • The Carlyle Group in its acquisition of MedRisk, a leading provider of tech-enabled services to payors, TPAs and providers in the workers’ compensation space.
    • Deutsche Bank Securities, as financial advisor to Halyard Health, in the $710 million sale of Halyard’s surgical and infection prevention business to Owens & Minor.
    • J.P. Morgan Securities, as financial advisor to Akorn, in the $4.3 billion sale of Akorn to Fresenius Kabi. (Terminated)
    • Sawai Pharmaceutical in its $1.5 billion acquisition of the generic pharmaceuticals business of Upsher-Smith Laboratories.
    • Clayton, Dubilier & Rice in the acquisition of Carestream Dental, an industry-leading provider of dental digital product lines and services, from Carestream Health/Onex.
    • J.P. Morgan Securities, as financial advisor to Surgical Care Affiliates, a leading ambulatory surgery center and surgical hospital provider, in the $2.3 billion combination of Surgical Care Affiliates with Optum, a leading health services company and part of UnitedHealth Group.
    • Johnson & Johnson in its purchase of an exclusive option to acquire Bird Rock Bio, a clinical stage biopharmaceutical company focused on innovative immuno-inflammatory regulators that can be used in the treatment of liver disease.
    • Clayton, Dubilier & Rice in the formation of agilon health, a new healthcare technology and services platform, through the acquisition and merging of Primary Provider Management and Cyber-Pro Systems.
    • Johnson & Johnson in its acquisition from AstraZeneca of the global rights outside of the U.S. to Rhinocort Aqua, a line of nasal sprays used to treat allergies.
    • The Board of Directors of Monsanto in its $66 billion sale to Bayer.
    • Allergan in its $639 million acquisition of Vitae Pharmaceuticals, a clinical-stage biotechnology company.
    • Clayton, Dubilier & Rice in its acquisition of a controlling stake in Drive DeVilbiss Healthcare, a leading global manufacturer of medical products.
    • Providence Service Corporation in a strategic partnership with Frazier Healthcare Partners in Matrix Medical Network.
    • Envision Healthcare in its $15 billion merger with AMSURG, creating one of the largest U.S. providers of specialty physicians and hospital-related services.
    • Ally Bridge in its PIPEs transaction with Nasdaq-listed Sorrento Therapeutics, a U.S. biotechnology company.
    • Nestlé Skin Health in its $1 billion acquisition of Guthy Renker’s worldwide Proactiv business, the world’s leading non-prescription acne brand.
    • Johnson & Johnson in the sale to SK Capital Partners of its global narcotics business.
    • Precision For Medicine in the $75 million investment in the company by TPG Growth.
    • Capital International in its approximately $200 million acquisition of a minority stake in Mankind Pharma, an Indian pharmaceutical company.
    • Lannett in its acquisition for $1.23 billion in cash, plus additional contingent consideration, of Kremers Urban Pharmaceuticals, the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB.
    • Guggenheim Securities and Goldman Sachs, as financial advisors to Pfizer, in its $160 billion acquisition of Allergan. (Terminated)
    • PharMEDium, a Clayton, Dubilier & Rice portfolio company and the leading national provider of outsourced compounded sterile preparations to acute care hospitals in the United States, in its $2.6 billion sale to AmerisourceBergen.
    • Theragen, a privately owned medical device company, in its acquisition of Neurotech North America.
    • Envision Healthcare in its $620 million acquisition of Rural/Metro Corporation, the second largest provider of ambulatory services in the U.S.
    • J.P. Morgan Securities, as financial advisor to Allergan, in Allergan's $40.5 billion sale of a generics unit to Teva Pharmaceutical Industries.
    • Pediatric Services Holding Corporation, the parent of Pediatric Services of America, in its sale to J.H. Whitney Capital Partners.
    • Healogics, a Clayton, Dubilier & Rice portfolio company, in its acquisition of Accelecare Wound Centers.
    • Actavis in the sale of its branded respiratory business in the U.S. and Canada to AstraZeneca for $600 million, and an additional payment of $100 million in connection with certain other agreements.
    • J.P. Morgan Securities, as financial advisor to Salix Pharmaceuticals, in the $15.8 billion sale of Salix Pharmaceuticals to Valeant Pharmaceuticals.
    • Actavis in the sale of Aptalis Pharmaceutical Technologies, a pharmaceutical outsourcing and R&D business in the U.S., to TPG.
    • Morgan Stanley, as financial advisor to NASDAQ-listed life science and technology company Sigma-Aldrich, in the $17 billion acquisition of Sigma-Aldrich by Merck KGaA.
    • Forest Laboratories in its sale of the generic drug Propranolol to Catalent.
    • Diamond Castle in the acquisition by its portfolio company Beacon Health of ValueOptions, the largest independent behavioral healthcare and wellness company in the U.S.
    • Alliance Boots in tax matters relating to the possible tax inversion of Walgreens.
    • Stone Point Capital in its sale of Genex, a provider of healthcare and disability management services, to Apax Partners.
    • Clayton, Dubilier & Rice in its $910 million acquisition of Healogics, the largest advanced wound care services provider in the U.S.
    • Johnson & Johnson in the sale of its worldwide intimate health business to Reckitt Benckiser, a UK-based consumer goods company.
    • Forest Laboratories in its $2.9 billion acquisition of Aptalis, a gastrointestinal and cystic fibrosis company, from TPG.
    • Clayton, Dubilier & Rice in its acquisition of PharMEDium, a leading provider of sterile compounding services to hospital pharmacies.
    • StoneRiver Group in the formation of a joint venture with funds managed by Kelso & Company in which StoneRiver Group’s Progressive Medical was merged with PMSI.
    • Diamond Castle in its $1 billion sale of MHA to Roper Industries.
    • AssuraMed in its $2 billion sale to Cardinal Health.
    • Noven Pharmaceuticals in its acquisition from Novartis of the commercial rights to Minivelle, an estradiol transdermal system, in the U.S. and Canada.
    • Galderma Pharma in its agreement with Valeant Pharmaceuticals to restructure certain North American licensing arrangements in connection with Valeant's $2.6 billion acquisition of Galderma's long-time partner Medicis Pharmaceutical.
    • Catalent Pharma Solutions in tax matters relating to its acquisition of the remaining 49% interest in R.P.Scherer GmbH & Co.KG from Gelita AG.
    • Oceana Therapeutics in its sale to Salix Pharmaceuticals.
    • Forest Laboratories in its acquisition of the Colistin business of Grünenthal GmbH.
    • Tenet Healthcare in its successful effort to block a hostile takeover bid by Community Health Systems, a competing investor-owned hospital company.
    • Clayton, Dubilier & Rice and GS Capital Partners in their acquisition of HGI Holdings, a leading distributor of medical products to chronic disease patients, from The Jordan Company and members of the Harrington family.
    • Clayton, Dubilier & Rice in its $3.2 billion acquisition of Emergency Medical Services Corporation.
    • The Board of Directors of Eclipsys in its $1.4 billion merger with AllscriptsMisys Healthcare Solutions.
    • Michael Pearson, the CEO of Valeant Pharmaceuticals International, in Valeant Pharmaceuticals International’s $3 billion merger with Biovail Corp.
    • Galderma Pharma in its acquisition of the Metvix and Metvixia dermatology products from Photocure ASA.
    • United BioSource in its growth equity investment from Berkshire Partners.
    • Hisamitsu Pharmaceutical, a leading transdermal patch manufacturer listed on the Tokyo stock exchange, in its $428 million acquisition of Nasdaq-listed Noven Pharmaceuticals via an all-cash tender offer.
    • Kelso & Company in its acquisition of a portfolio of medical products from Q-Med.
    • Johnson & Johnson in its acquisition of the remaining 50% stake in Vania Expansion, S.N.C. and Laboratoires Polive S.N.C. from Georgia-Pacific Corporation.
    • Misys in the combination of its healthcare business with Allscripts Healthcare Solutions, resulting in Misys owning a 54.5% interest in Allscripts-Misys Healthcare Solutions.
    • Galderma in its $420 million cross-border cash tender offer for Collagenex Pharmaceuticals.
    • Teachers’ Private Capital in its $1.65 billion acquisition with Ares of GNC.
    • Barclays Capital, as financial advisor to Pfizer, in Pfizer’s $68 billion acquisition of Wyeth.
    • Guggenheim Securities, as financial advisor to Pfizer, in Pfizer's $2.38 billion sale of Capsugel, a leading maker of hard capsule and other drug-delivery systems, to Kohlberg Kravis Roberts.
    • Lauro Cinquantasette in its €315 million sale of Prime European Therapeuticals to Albany Molecular Research.
    • United BioSource, a Whitney, Oak Hill and Berkshire Partners portfolio company, in its $730 million sale to Medco Health Solutions.
    • Kelso & Company in its going private acquisition of Del Laboratories, a company that distributes a wide variety of cosmetics under brand names and over-the-counter pharmaceutical products.
    • An investor in the $113 million taking private of a pre-clinical trial company.
    • Clayton, Dubilier & Rice in its $1.7 billion purchase of VWR International Corporation, a laboratory supplies distributor, from Merck and the sale of VWR International to Madison Dearborn Partners.
    • An investor in a series C round of funding for an applied clinical pharmacogenomic services provider.
    • Allergan in its $2.47 billion acquisition of ZELTIQ, a medical technology company focused on utilizing its proprietary CoolSculpting controlled-cooling technology platform, the sales leader in the fast-growing body contouring segment of medical aesthetics.
    • Lehman Bros as financial advisor in numerous transactions, including Thermo Electron’s $10.6 billion acquisition of Fisher Scientific Industries to create Thermo Fisher Scientific, Medco Health Solutions’ $2.3 billion acquisition of Accredo Health, the special committee of Triad Hospitals in its $6.8 billion acquisition by Community Health Systems, Sierra Health Services in its $2.6 billion acquisition by UnitedHealth and MGI PHARMA in its $3.9 billion sale to Eisai.
    • Allergan in its $2.9 billion acquisition of LifeCell Corporation, a regenerative medicine business.
    • Actavis in its acquisition of Nasdaq-listed Durata Therapeutics, a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses, for $675 million plus contingent value rights.
    • Nestlé in its $1.4 billion acquisition of the aesthetic dermatology business of Valeant Pharmaceuticals.
  • Licensing, Development And Commercialization

    • Johnson & Johnson in its global co-development and commercialization agreement with Theravance Biopharma, relating to various compounds being developed for the treatment of inflammatory bowel disease, including Crohn's and ulcerative colitis.
    • Allergan in its global collaboration agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic.
    • Galderma Pharma in its agreement with NovaBay Pharmaceuticals to develop and commercialize NovaBay's novel Aganocide drugs for major dermatological conditions.
    • Gen-Probe in its collaboration agreement with Pacific Biosciences of California in the research and development of third-generation DNA testing systems for use in disease diagnosis and blood screening.
    • Galderma Pharma in its licensing arrangement with Nuvo Pharmaceuticals (formerly ZARS Pharma) relating to the promotion and distribution of a topical anesthetic cream, Pliaglis, in North America and in the subsequent extension of that agreement to cover worldwide rights.
    • One of the world’s largest pharmaceutical companies in its supply agreement with Baxter Healthcare.
    • Hologic (formerly Gen-Probe) in its collaboration agreement with Pacific Biosciences of California in the research and development of third-generation DNA testing systems for use in disease diagnosis and blood screening.
    • Galderma Pharma in its worldwide development and commercialization agreement with Anika Therapeutics.
  • Capital Markets And Finance

    • agilon health and Clayton, Dubilier & Rice in the $586.5 million secondary offering of agilon health common stock.
    • Lannett Company in its $585 million comprehensive refinancing.
    • agilon health in its $1.2 billion initial public offering.
    • Vets First Choice in the financing aspects of its merger with the Henry Schein Animal Health business to create Covetrus, a new standalone public company.
    • Envision Healthcare in its $1.1 billion initial public offering of common stock.
    • Envision Healthcare, a Clayton, Dubilier & Rice portfolio company, in its offering of $750 million of senior notes.
    • Lazard-Natixis, UBS Investment Bank and Piper Jaffray in NicOx's €100 million private placement of shares to Fonds Stratégique de Soutien and public rights offering.
    • Del Laboratories, a Kelso & Company portfolio company, in its exchange offer for floating rate secured notes.
    • AIG Altaris Health in senior financing relating to the equity recapitalization of Sparta Systems by Summit Partners and AIG Altaris.
    • One of the world's largest pharmaceutical companies in its convertible debt investment in Monogram Biosciences and related Collaboration Agreement.
    • Investors in HealthSouth’s $400 million offering of 6.5% Series A convertible perpetual preferred stock.
    • Bear Stearns and Citigroup as lead underwriters in Endo Pharmaceuticals’ $868 million secondary offering of shares.
    • Goldman Sachs and Calyon as lead managers in the €1.5 billion initial public offering of bioMerieux, listed on the Premier Marche of Euronext.
  • Traditional Products Liability

    • Allergan in defeating nationwide class certification of a putative class of third-party payors alleging violations of federal RICO statutes through fraudulent promotion of antidepressants.
    • Bristol-Myers Squibb in defending against a $3.4 billion contract and tort claim by generic drug manufacturer Apotex, winning a unanimous jury verdict of no liability.
    • Forest Laboratories in an investigation regarding disclosure of clinical studies regarding the safety and efficacy of anti-depressant medication used by children and adolescents.
    • GE Healthcare in litigation arising from its $8.13 billion acquisition of the Diagnostics Division Business and the Abbott Point of Care Business from Abbott Laboratories.
    • The former CEO and Chairman of one of the world’s largest pharmaceutical companies in proceedings brought by the Nigerian government related to the antibiotic Trovan.
    • Tambrands in defending several hundred toxic shock syndrome cases. In this capacity, we handled every aspect of the company’s cases throughout the country, as well as in Canada, the United Kingdom and Australia, including formulating national strategy; preparing cases for trial and trying the cases; selecting and preparing all company witnesses and expert witnesses; negotiating or supervising local counsel in negotiating all settlements and handling all related appellate work.
    • Wyeth and American Home Products, as a member of its multi-firm national defense team, for the diet drug litigation, with oversight for cases filed in several Southeastern states and alleging cardiac and pulmonary injuries.
  • White Collar Defense and Internal Investigations

    • A multinational life sciences company in internal investigations relating to corruption allegations regarding Russian and another CIS subsidiary.
    • Global pharmaceutical company in investigations led by DOJ and U.S. Attorney's Office (E.D. Wisc.) relating to sales practices, and related False Claims Act litigation.
    • A major pharmaceutical company in investigations led by DOJ and U.S. Attorney's Office (D. of Mass.) relating to drug marketing and distribution, and related False Claims Act litigation.
    • A major hospital corporation in civil and criminal matters arising out of the nationwide recall of an adulterated prescription medication.
    • A multinational pharmaceutical company’s Board of Directors in internal investigation relating to product development, testing, and marketing.
    • A major pharmaceutical company in threatened exclusion of CEO from federal healthcare programs.
    • A multinational pharmaceutical company Chairman and CEO in drug marketing investigation led by U.S. Attorney's Office (D. Mass.).
    • A major pharmaceutical company executive in investigation led by DOJ and U.S. Attorney’s Office (M.D. Fla.) relating to medical device promotion.
    • A multinational pharmaceutical company in securities fraud investigation led by U.S. Attorney's Office (D. N.J.) relating to product distribution.
    • A leading pharmaceutical company in parallel SEC and Department of Justice investigations of alleged earnings management/securities fraud, as well as in internal investigations and FCPA compliance advice.
  • Global and U.S. Compliance

    • Multiple multinational pharmaceutical companies in internal investigations and provision of FCPA compliance advice.
    • Independent FCPA consultant to Schering-Plough Corporation, appointed pursuant to consent of the Company and the SEC.
    • A major pharmaceutical company in negotiating, implementing, and facilitating ongoing compliance with Corporate Integrity Agreement.
    • A multinational pharmaceutical company’s Board of Directors in conducting several Compliance Program effectiveness reviews to support Corporate Integrity Agreement obligations.
    • A global pharmaceutical company in conducting internal assessment of senior executives’ role in Compliance Program.
    • The board of a leading medical device manufacturer in a series of compliance effectiveness reviews, and a review of the board’s governance practices.
    • A global technology company’s Board of Directors in independent FCPA investigation and review of medical equipment and diagnostic businesses.
  • Intellectual Property

    • A major healthcare company in advice related to regulatory and governance issues around artificial intelligence.
    • Novartis and Bayer in obtaining injunctions against foreign website operators who were selling gray market pet medicines to U.S. consumers via the Internet.
    • Galderma in review of a paragraph IV certification for an Abbreviated New Drug Application filed by Actavis, advice on an infringement of its Clobex product's formulation patent, and pursuit of patent infringement litigation if it appears that Actavis' proposed generic corticosteroid lotion will infringe on the Galderma patent.
    • Nestlé in back-to-back victories in false advertising disputes over advertising for Ross’s Isomil Advance and Similac EarlyShield baby formulas.
    • Alcon Laboratories in the successful defense of a preliminary injunction sought by Pharmacia Corporation to enjoin the launch of Travatan.
    • Alcon in successful challenges in court and before the NAD against Bausch & Lomb advertising that falsely disparaged Alcon’s Opti-Free Express contact lens solution.
    • Warner Lambert and Tambrands in advertising disputes related to pregnancy test kit technology.
    • Bayer, in false advertising challenges against Summit VetPharm and Elanco regarding advertising claims for the animal health products.
    • Novartis in a long string of false advertising victories in the NAD for smoking cessation products, anti-fungal products, antacids, medical foods and decongestants.
    • Galderma in an arbitration related to a license dispute for a dermatology drug.
    • Gerber and Bayer in cybersquatting disputes challenging usage of trademarks in third parties’ domain names.
    • Alcon in false advertising disputes against Bausch & Lomb involving reports of scientific studies on corneal staining.
    • Ciba in defending against a false advertising challenge filed by Johnson & Johnson related to consumer preference for the parties’ contact lenses.
    • Bowthorpe in a theft of trade secrets case related to a medical device.
  • Civil Litigation and Dispute Resolution

    • Major pharmaceutical company in multiple consumer fraud class actions, including defeating nationwide class certification and state-wide certification in multiple states.
    • Major healthcare services company in multiple class actions relating to billing practices.
    • Global pharmaceutical company in multiple qui tam actions brought under the False Claims Act.
    • A major pharmaceutical company in shareholder derivative and securities class action relating to drug marketing and disclosure of study results.
    • A multinational pharmaceutical company in dispute relating to manufacturing and supply of vaccines.
    • Multinational healthcare company in disputes relating to European consumer product rights.
    • A Special Committee of the Board of Directors of a major U.S.-based pharmaceutical company in responding to a derivative demand letter broadly alleging misconduct, including securities violations, insider trading and fraud, arising in connection with the results of a clinical trial.
  • International Dispute Resolution

    • A major pharmaceutical company with advice at board-level concerning worldwide supply chain issues, including delay and quality concerns resulting in severe disruption caused to its global vaccines business, resulting in a successful settlement avoiding lengthy arbitration proceedings.
    • A major pharmaceutical company in litigation alleging material breaches and unilateral termination of a commercial supply agreement for the development and manufacture of a vaccine.
    • One of the world’s largest pharmaceutical companies in an AAA arbitration under English law relating to a collaboration agreement to develop new drugs.
    • A leading French pharmaceutical manufacturer in settling on favorable terms a dispute arising out of a distribution agreement with a Moroccan company.
    • IMS Health Incorporated and its Latin American affiliates in a Spanish-language ICC arbitration relating to an alleged breach in Brazil, Mexico and certain other Latin American jurisdictions of a contract governed by Argentine law.
    • A leading pharmaceutical manufacturer in arbitration/litigation against an international paper products manufacturer concerning joint marketing agreements in France.
    • A multinational pharmaceutical company in obtaining a successful defense verdict in $3.5 billion contract dispute.
    • A consumer products company as national trial counsel defending several hundred personal injury suits.
    • A major pharmaceutical company in consumer fraud class actions, including defeating nationwide class certification.
    • Pharmaceutical and health products companies as a member of the national defense team defending product suits.
    • A major, global pharmaceutical company in an arbitration involving cross-licenses and product development.
    • A major global pharmaceutical company in various claims relating to patent issues.
    • A major, global pharmaceutical company in a dispute involving distribution of products in China.
    • A pharmaceutical company in royalty disputes.